Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Benitec Biopharma (BNTC) EBIT Margin (2019 - 2023)

Historic EBIT Margin for Benitec Biopharma (BNTC) over the last 5 years, with Q2 2023 value amounting to 65000.0%.

  • Benitec Biopharma's EBIT Margin changed N/A to 65000.0% in Q2 2023 from the same period last year, while for Mar 2024 it was 307028.57%, marking a year-over-year decrease of 2786918100.0%. This contributed to the annual value of 25441.33% for FY2023, which is 9838000.0% down from last year.
  • According to the latest figures from Q2 2023, Benitec Biopharma's EBIT Margin is 65000.0%.
  • Benitec Biopharma's 5-year EBIT Margin high stood at 8248.57% for Q2 2020, and its period low was 379300.0% during Q1 2021.
  • For the 5-year period, Benitec Biopharma's EBIT Margin averaged around 80620.4%, with its median value being 8038.89% (2023).
  • As far as peak fluctuations go, Benitec Biopharma's EBIT Margin plummeted by 2000000000bps in 2021, and later soared by 2000000000bps in 2022.
  • Benitec Biopharma's EBIT Margin (Quarter) stood at 2741.56% in 2019, then tumbled by -11787bps to 325900.0% in 2020, then skyrocketed by 94bps to 19340.0% in 2021, then tumbled by -107bps to 40071.43% in 2022, then tumbled by -62bps to 65000.0% in 2023.
  • Its EBIT Margin was 65000.0% in Q2 2023, compared to 8038.89% in Q1 2023 and 40071.43% in Q4 2022.